US FDA Filing Mistake For Fintepla Dents Zogenix

 
• By Alexandra Shimmings

Zogenix seems only to have itself to blame for an unexpected refusal to file letter from the US agency for its novel treatment for Dravet syndrome that sent its shares tumbling by 31% on NASDAQ in after-hours trading.

SpiltMilk
Zogenix tries to look past Fintepla FDA filing mistakes • Source: Shutterstock

More from New Products

More from Scrip